Consumer concerns: Give us all the data! by Hansen, Michael
CONSUMER CONCERNS 
GIVE US ALL THE DATA*
I am not going to focus on public concerns about all of agricultural bio-
technology but primarily on bovine growth hormone or bovine somato-
tropin (BST). I do this because BST is going to be the first major product 
in agricultural biotechnology to come out—if it is approved. There has 
been a lot of controversy surrounding this 
product, and I think there is a lot of consumer 
concern about BST.
I would like to raise a couple of general issues 
and then spend time discussing a number of in-
ternal documents from the Food and Drug Ad-
ministration (FDA)—letters and memoranda 
sent to companies that paints a very different 
picture of some of the problems with BST than 
what has come out publicly.
CONSUMER PERCEPTIONS OF BIOTECHNOLOGY
A number of studies have shown that consum-
ers are very wary about new technologies and in fact, are very wary about 
biotechnology. In a survey that was done for the National Dairy Board in 
1986, one of the conclusions was “that the strongest impression in the con-
sumers’ mind is that most problems are result of man’s [sic] interference 
with nature, a tampering with the natural order of things for the sake of 
profit or convenience or both.” Some of the people who have criticized the 
media and criticized the critics of biotechnology have tended to say that 
the problem with the general public is that they are very uninformed. If 
only they were scientifically more literate, they would understand this 
technology and come to accept it. I think that consumers are not as igno-
rant as a lot of people might think.
A study done for the National Dairy Board in 1990 asked consumers 
about their awareness of a number of issues and how important they felt 
that issue was (i.e., whether they were concerned with it or not). Two
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things can be seen. A large percentage of consumers were aware of both 
the Alar® contamination of apples and the recall of grapes from Chile be-
cause of cyanide contamination—83 and 85 percent respectively. If you 
look at the number of consumers, of the percent that were not concerned 
about those issues, among those that were aware, you find it is fairly 
significant—27 percent and 29 percent. When you look at other issues 
which I think are more important than either the Alar® scare or the recall 
of grapes from Chile, you see that for Salmonella in fresh poultry, drugs 
given to cattle, the use of hormones to increase milk in dairy cows or the 
antibiotics used to treat livestock that are harmful to humans—there is a 
smaller percent awareness of those issues in general. Yet the percentage of 
consumers who do nor think that issue is a problem (if they know about it) 
is much smaller. What this shows is that the consumers are a little bit more 
aware than some people give them credit for. Of those that were aware of 
the Alar® controversy and the recall of grapes from Chile, more than 2V2 
times those people were not concerned relative to concerns over drugs given to 
cattle, the use of the bovine growth hormone and antibiotic questions.
WHO DO CONSUMERS TRUST?
Let us now look at who consumers tend to trust. A survey in Dairy Today 
in 1990 asked, “Who would you trust regarding BST safety?” Eighty-four 
percent said that they would trust consumer safety groups, 54 percent uni-
versity researchers, 45 percent the American Medical Association and 34 
percent the FDA. The family doctor is the number one person that con-
sumers trust for sources of information about the safety of food. Con-
sumer Reports is number two. The drug companies are at the bottom of the 
list. It seems as though consumers are not very trustful of the companies. 
They also are not trustful of FDA. Is there is a reason for that? I think that 
indeed there might be. In 1990 the National Dairy Board asked consumers 
questions after they were given information in the form of statements on 
BST. Only 25 percent of the consumers agreed with the statement “milk 
from cows treated with BST is completely safe”; 83 percent agreed with the 
statement “the long-term or the long run health implications of BST are 
not known”; only 29 percent agreed with the statement “testing has shown 
that the milk from cows treated with BST is completely safe”; and 63 per-
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cent agreed with the statement “milk from the cows treated from BST may 
be harmful to humans.” This survey shows there is a lot of concern out 
there among consumers.
BST AND SECONDARY DRUG RESIDUES
Now, we have to ask, is this concern legitimate or is it based on not much 
information? If you look at the studies which have come out they have 
tended to say that there is not a problem with BST (i.e., with the consum-
ing of milk and meat products from the experimental test herds). In fact, 
in 1986, when the FDA made the decision that there were no human health 
impacts and therefore permitted the marketing of milk from these experi-
mental test animals, there was a lot of controversy. Since then there has 
been an article published in Science magazine and most recently, an Office 
of Technology Assessment (OTA) report came out which basically said 
that there is no concern for human health. Concerns are my work in this 
area—the main problem I have with FDA’s position is the one thing they 
have missed—a primary human health concern with the potential for the 
secondary drug residues in milk. (I also have some concerns about insu- 
lin-like growth factor, but will not discuss them here.) The concern about 
drug residues arises when the animals treated with BST and if there is an 
increase in mastitis and other bacterial infections, then that could lead to 
increased use of antibiotics, which in turn leads to antibiotic residues in 
milk. This is a very important issue.
The Government Accounting Office (GAO) late 1990 released a report 
which says that FDA cannot guarantee the safety of the milk supply, and 
that their testing procedures are highly flawed and do not pick up a lot of 
antibiotics. I have been told, off the record, by people from the dairy in-
dustry that they are concerned about the unregulated drug use in animal 
agriculture. The FDA, also off the record, admitted that there is a concern 
there. So our position and concern at Consumers Union is that if this 
technology can be shown to increase disease rates in these cattle, then that 
in turn potentially can lead to greater contamination in milk with antibi-
otic residues. If that is a significant human health concern, then how can 
FDA say that there are no human health effects when they have not explic-
itly looked at that issue? Further, the FDA has explicitly not yet discussed 
whether there are any health impacts on the cows.
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Quoting now from the OTA report, which came out this spring, on the 
effects of bovine health and stress, “catastrophic effects such as the instance 
of ketosis (which is under production of glucose) fatty liver, crippling 
lameness, milk fever (which is feverish disorder following parturition), 
mastitis (inflammation of the udder), sickness, suffering and death have 
all been postulated to occur with BST.” This is the important part—“how-
ever, no such effects have been observed with BST supplementation of 
dairy cows in any scientifically valid published study, nor have subtler 
health effects been in evidence.” So what OTA is saying is that there is no 
evidence whatsoever of problems such as mastitis. Now, I tend to think 
that there is some evidence of such problems. I base this belief on internal 
documents from the FDA and other papers.
In a memorandum of a meeting between representatives from Monsan-
to and representatives from the Center for Veterinary Medicine, the first 
line says, “Mr. Matheson requested this meeting in order to formally re-
quest the preparation of an environmental assessment for this and all 
other INADs.” An INAD is an Investigational New Animal Drug. An INAD 
had been filed by Monsanto which involved the use of recombinant DNA 
technology in the production of a new animal product. That new product 
is bovine growth hormone. By law, these environmental assessments 
should be done before an INAD is granted. The first INAD for Monsanto 
was granted around 1983. Did they prepare an environmental assessment? 
No.
The second page of this memorandum addresses the petition submitted 
by the Foundation on Economic Trends. In March of 1986, the Foundation 
on Economic Trends and sixteen other groups signed onto a petition that 
demanded that FDA do an environmental impact assessment on bovine 
growth hormone. FDA turned down their petition saying that an environ-
mental assessment and an environmental impact statement had already 
been prepared. The groups then petitioned, using a freedom of informa-
tion act, to get copies of the environmental assessments. FDA said, “sorry, 
that’s trade secrets, we cannot release this.” The Foundation took them to 
court, 2V2 years later, the documents were released. FDA had told the com-
pany that the environmental assessment and CMDs findings would re-
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main in the INAD unless disclosure was required through court proceed-
ings. This indicates that FDA internally knew that things like environmen-
tal assessments and health effects are not legitimate confidential business 
information, but was going to make people sue them to get the informa-
tion out.
Now I am going to go on to deal with two sets of letters. They are from 
FDA, the first set to Eli Lilly and the second set to Monsanto. These are 
what are called New Animal Drug Application (NADA) incomplete let-
ters. The way the regulatory system works, you get an INAD permit which 
permits you to ship a drug across state lines and gather data in farmers' 
fields and at universities. After that data is gathered and submitted to the 
agency, the company then submits a NADA asking the agency to let them 
sell this product and to make a given label claim. In Eli Lilly’s letter of Oc-
tober 8, 1987, they requested approval to market a sustained release subcu-
taneous injectable BST with the claim of increasing milk production and 
improved feed efficiency. The FDA told them that the submission was in-
complete, making specific comments. I want to highlight a few things in 
this letter that caused us to be very upset. The first thing has to do with the 
efficacy. In this letter, FDA talked about a serious error in the milking pat-
tern in the Canadian trial. Critics of this research have talked about how 
there has been manipulation of data to show that there is not any problem 
or to show that the drug works. In this Canadian trial they were establish-
ing what the optimal milking interval was for the highest producing cow. 
They used that milking interval with lower producing cows although it 
was suboptimal for them and could be detrimental to the milk yield. What 
the researchers said is that the cows were continually moved such that the 
top producers were exposed to a near ideal milking interval, while the low 
producers’ milk yields were probably diminished due to a wide milking 
interval. Logically, control animals would, on average, end up with the 
lower producers, particularly by the end of the lactation, while BST 
treated cows would be among the top producers. The continual move-
ment of cows throughout the length of the study prevented any possibility 
of factoring out this problem. Thus there was a bias in the way that the 
study that was done.
A French study commented on by FDA looked at the effect of BST on 
milk composition. It demonstrated no alteration or no effect on the fatty
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acid content or the protein content of milk. However, FDA had to point 
out to Eli Lilly that this data was not very useful because just the milk yield 
was not changed by treatment and there were no differences between the 
treated cows and the experimental cows. It is not feasible to extrapolate 
those milk composition results to a situation where milk production was 
increased by BST. Again, a flawed study. The summary of sensitization 
studies stated that the product (milk) elicited a positive sensitization re-
sponse. The same thing was brought up in the Monsanto letter. In the ani-
mal health and reproduction target animal safety section of the FDA letter 
to Eli Lilly, it says point blank, “We are concerned about the increased in-
cidents and duration of mastitis and reproductive parameters in the field 
studies.”
Now let us turn to the Monsanto letter. Again, Monsanto was trying to 
get FDA approval. They sent in all their data asking for approval to market 
this product (BST) and to make label claims of increased milk production 
and increased feed efficiency. All of their data that was sent in says because 
no statistical differences were found between treatment groups for feed 
efficiency, they did not bother to review the data further. That is very curi-
ous. All the data that Monsanto had sent in, as of late 1987, could not 
demonstrate any differences in feed efficiency. Yet if you look in the litera-
ture, there are all these studies which demonstrate increases in feed effi-
ciency. It is interesting that this negative result never appeared in the lit-
erature.
When we go to the target animal safety section of the Monsanto letter, 
FDA discusses the problems with mastitis—in 3C, it says “you should ad-
dress the use of gentomycin and tetracycline, which are not approved for 
the treatment of mastitis in dairy cattle.” Critics have pointed out that in-
ternal documents leaked from Monsanto indicated that there was use of 
drugs which were not permitted in dairy cattle. The letter continues, “the 
overall conclusion for the mastitis was data presented indicates that there 
was an increase in mastitis at levels at which you wish to market bovine so-
matotropin”. Responding to the reproductive data FDA says that you have 
compromised the usefulness of your reproductive data by the use of pros-
taglandins and progesterone assays. It is not possible to evaluate the effect 
of BST on reproduction if concurrent use of reproductive hormones in di-
agnostics tests masks or otherwise alters the effect of the drug. In 4B of this
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letter it talks about the data indicating that the regimen outlined in their 
protocols was not adhered to and in 4C it indicates that the use of pros-
taglandins varied in time, frequency and reasons for use, and were used 
for unapproved claims such as metritis. “Some cows”, the letter said, “re-
ceived a drug that was not approved for use in dairy cattle.” The overall 
conclusion was that “your data indicates that there are reproductive prob-
lems at the doses at which you wish to market bovine somatotropin.” 
Turning to injection site syndrome, FDA said that the data indicated 
that the severity of injection site response increases with time. In 5C it 
continued, “your data indicate that there may be an unacceptable level of 
tissue reaction with prolonged use of BST in the range of doses for which 
you wish approval. Lameness and displaced abomasum maybe drug re-
lated. You (Monsanto) have not established a margin of safety, nor have 
you established a no effect level for some of the parameters in your sub-
mission.” Based on available data, this is particularly true of major clinical 
entities such as mastitis and reproduction. Remember, FDA is saying that 
Monsanto could not demonstrate a “no effect” level. The letter concludes 
with “if you seek approval of a range of 250 to 500 milligrams in cows or 
heifers, you may not even have a 1-fold margin of safety. Under current 
standards, this is unacceptable for an over-the-counter approval.” On the 
last page of the letter, FDA talks about mitigation measures. They say “you 
should describe steps you (Monsanto) are taking, including labeling, to 
present sensitization by those occupationally exposed to the BST protein.” 
So, both of these letters, one to Eli Lilly and one to Monsanto, indicate 
that there seem to be problems. In fact, two weeks after the latter letter was 
sent, there was a meeting between Monsanto and the FDA to talk about 
the target animal safety portion of this NADA incomplete letter. Dr. 
Lehman, head of the production division of the drug section, very clearly 
expressed concern over the increase in days that cows were affected by 
mastitis during the BST treatment. Again noting that there was mastitis. 
Concern was also raised over injection site swelling. The use of reproduc-
tive agents was discussed. Some drugs may be used for clinical conditions; 
however, they also are used to get cows pregnant to cover up reproductive 
problems. There was a lot of concern there. About a year later, there was a 
memo written by Dr. Guest after meeting with the National Milk Produc-
ers Federation. In it, they are talking about how to manage the consumer
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perception. They ask that in view of the likely problems with cattle safety 
and the need for careful management of the cattle, should the product be 
prescriptioned? It was also asked whether prescriptioning BST might also 
give some sense of security to the consumer. My concern with a lot of 
these documents, and I think Consumers Union’s too, is how can the OTA 
say that there is no evidence whatsoever that there are problems such as 
mastitis with BST use when, internally, it seems like FDA is saying that 
there are problems with mastitis and with reproduction. Unfortunately 
none of this data was made public.
Now, those letters that I discussed (shown as slides at the meeting) are 
three years old. Maybe I am willing to admit that companies have been 
able to overcome these problems discussed above in the last three years. 
But the problem I still have is why is it that none of the negative effects 
discussed in these letters have never made it into the literature? And if the 
companies and the FDA want to tell us that there is not any problem, why 
should we trust them?
GAINING TRUST
What I think needs to happen, if you want consumers to have some 
trust in what you are doing, is the data has to be made readily available. 
Consumers have the right to know about health impacts. I think that the 
data on the adverse effects of BST not being made public while all the 
positive data is being made public. This is of a lot of the public’s concern. 
We would like to see all the health and safety data released to the public. I 
would just like to say to those other companies working on applications of 
biotechnology—make your data public, try to be up front with the critics.
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